Latest news with #Savary
Yahoo
15-07-2025
- Business
- Yahoo
Which European economy stands to suffer the most from US tariffs?
Germany and Ireland are standing out as the two most exposed EU economies threatened by higher US tariffs, as Brussels works towards a trade deal with Washington, amid reports that pharmaceutical tariffs could be as high as 200%. When US President Donald Trump imposed a new 25% tariff on auto imports and car parts in April, Germany was identified as the EU country with the most to lose. Brussels-based think tank Bruegel's estimation at the time was that tariffs could cost 0.4% of the country's GDP in the long term. While awaiting a new EU-US trade deal, other details emerge that could put Ireland, Denmark, and Belgium, as well as other countries, in the crosshairs should Washington target the pharmaceutical sector next. The overall impact on the European economy will depend on the actual tariff rate the US settles on and the EU's response, but the blow will not be spread evenly. According to Bruegel, the EU economy is facing significant but manageable macroeconomic consequences. They estimated in a report in April that, regarding the possible scenarios, the damage could be approximately 0.3% of the EU's GDP, depending on the outcome of the negotiations. This compares to the 1.1% real GDP growth expected in the bloc in 2025, by the European Commission's Spring Forecast. Trade with the US is significant. In 2024, the United States was the largest partner for EU exports of goods, making up 20.6% of all EU goods exports outside the bloc. Pharmaceuticals account for 15% of the EU's goods exports to the US. They are followed by the auto sector. Until there is more clarification on potential US tariffs on the pharma sector's products, 'the auto sector seems to be the most vulnerable to US tariffs as there doesn't seem to be any major exemptions planned,' said Savary. The industry has been slapped with a 25% tariff in April. 'Tariffs alone could shave around 8% off total EU trade volumes over the next five years,' said Rory Fennessy, Senior Economist at Oxford Economics, in a recent report. Countries with the highest value in goods exports to the US, facing the biggest threat to their economies, include Germany, Ireland, Italy, France and the Netherlands. The German economy relies heavily on exports, boosted by the country's motor vehicle sector. Nearly one-quarter (22.7%) of the total German exports are heading to the US. 'Germany stands out as the major European economy likely to be hit hardest by US tariffs, and we expect GDP growth to slump in the second and third quarters," Andrew Hunter, Associate Director and Senior Economist at Moody's Ratings, said to Euronews Business. Hunter also added that smaller economies, including Austria and others in central and eastern Europe, 'which are heavily integrated into Germany's industrial supply chains, will also be hit hard'. According to Bruegel, after 2025, the long-term negative impact of the tariffs could be around 0.4% of the GDP in Germany, once 'the effect has fully built up and initial short-term effects dissipated,' said Niclas Frederic Poitiers, Research Fellow at Bruegel. 'For France, the average effect would be around 0.25% of GDP.' Related Lengthy trade wars could cut global investment by one-tenth, warn economists Trump the unifier? How Europe could benefit from Trump's policies Uncertainty could lead to lost investments and jobs across the entire 27-member bloc. Hunter said that, 'even for those countries where direct exposure to US exports is relatively limited, such as France or Spain, growth is still likely to be weighed down by global weakness and uncertainty. Regarding long-term impacts, Ireland stands out as one of the most affected countries, as more than half of its goods exports (53.7%) are directed towards the US market. A lot depends on whether the pharmaceutical sector will be hit with tariffs. If so, 'Ireland will be the EU economy most at risk from these tariffs,' said Mathieu Savary, chief strategist for our European Investment Strategy at BCA Research. The research-based pharmaceutical industry is a key asset of the European economy. It is one of Europe's top-performing high-technology sectors. It contributed €311 billion in gross value added (GVA) and 2.3 million jobs directly and indirectly to the European Union's economy in 2022, according to a recent study by PWC. And the US market is crucial to the European pharma sector. According to the European Federation of Pharmaceutical Industries and Associations, in 2021, North America accounted for 49.1% of world pharmaceutical sales compared with 23.4% for Europe. And more than one-third of EU pharma exports are going to the US. If the pharma sector is hit by a 25% tariff, as it is expected by Moody's in the coming months, 'most exposed would be a number of smaller European economies like Denmark, Belgium, Slovenia and Ireland, which are generally where we think the risks of recession in Europe are highest,' Hunter said. BCA Research's chief strategist added that in this case, 'Ireland is particularly exposed to this risk,' citing that exports to the US represent 18% of Ireland's GDP, and pharma exports represent nearly 55% of Irish exports. According to BCA, the impact 'could curtail 4% to 5% to growth over time'. Bruegel estimated that Ireland's cumulative real GDP loss could be 3% by 2028. The think tank also singled out the country as the most vulnerable regarding the impact of the US tariffs on employment. Regarding how vulnerable a country is to job losses in light of US tariffs, Bruegel said that Italy was the second most-exposed country, with a high exposure in transport equipment and a high level of exposed employment in fashion and car manufacturing. Italy would also have high exposure in pharmaceuticals. Trump said on Tuesday that pharmaceutical products imported to the US are facing a 200% tariff, without disclosing any further details. According to BCA's Savary, it is not likely, because 'that would massively increase the cost of healthcare for US consumers, which is already a major issue for voters.' He sees it as a 'strong message to foreign pharma companies to adjust their pricing down and invest into producing their drugs in the US.' Savary expects 'that FDIs into the US and drug prices reduction announcements will be the end result of these talks and threats'. 'The pressure is now on for drug companies to expand US production facilities so they are effectively on the doorstep of American customers,' said Dan Coatsworth, investment analyst at AJ Bell. Sign in to access your portfolio
USA Today
15-07-2025
- Sport
- USA Today
Iowa baseball pitcher Anthony Watts selected by Cardinals in MLB Draft
As the third Iowa baseball player chosen in the 2025 MLB draft following teammates Cade Obermueller, Daniel Wright, and Aaron Savary, Hawkeyes pitcher Anthony Watts has been selected by the St. Louis Cardinals. Just 15 spots after the Cleveland Guardians selected Savary in the 13th round, St. Louis used the No. 420 overall pick to select Watts in the 14th round on Monday from Atlanta, GA. The 6-foot-4, 175-pound right-handed native of Clive, Iowa, was primarily used as a relief pitcher out of the Hawkeyes' bullpen this past spring, posting a 4-4 record with a 4.72 ERA in 40 innings through 24 appearances. Watts also finished the season with 45 strikeouts, a career-low 19 base-on-balls, 27 hits allowed, and two saves. Watts' selection now increases the number of Hawkeye players drafted under head coach Rick Heller to 37. Watts joined the program before the 2023-24 campaign following one season with Creighton, which gives him one year of NCAA eligibility remaining. Similar to Savary, does not list an approximate pick value for Watts. However, he could elect to return to the Hawkeyes for a senior season by not signing with the Cardinals. If Watts were to sign a professional contract with St. Louis, he would finish his three-year college baseball career with an 8-8 record and a 4.33 ERA on 129 innings pitched through 11 starts in 59 appearances to go along with 129 strikeouts and three games saved. Contact/Follow us @HawkeyesWire on X (formerly Twitter) and like our page on Facebook to follow ongoing coverage of Iowa news, notes, and opinions. Follow Scout on X: @SpringgateNews
Euronews
11-07-2025
- Business
- Euronews
Which European economy stands to suffer the most from US tariffs?
Germany and Ireland are standing out as the two most exposed EU economies threatened by higher US tariffs, as Brussels works towards a trade deal with Washington, amid reports that pharmaceutical tariffs could be as high as 200%. When US President Donald Trump imposed a new 25% tariff on auto imports and car parts in April, Germany was identified as the EU country with the most to lose. Brussels-based think tank Bruegel's estimation at the time was that tariffs could cost 0.4% of the country's GDP in the long term. While awaiting a new EU-US trade deal, other details emerge that could put Ireland, Denmark, and Belgium, as well as other countries, in the crosshairs should Washington target the pharmaceutical sector next. Countries with the largest exposure to the US market The overall impact on the European economy will depend on the actual tariff rate the US settles on and the EU's response, but the blow will not be spread evenly. According to Bruegel, the EU economy is facing significant but manageable macroeconomic consequences. They estimated in a report in April that, regarding the possible scenarios, the damage could be approximately 0.3% of the EU's GDP, depending on the outcome of the negotiations. This compares to the 1.1% real GDP growth expected in the bloc in 2025, by the European Commission's Spring Forecast. Trade with the US is significant. In 2024, the United States was the largest partner for EU exports of goods, making up 20.6% of all EU goods exports outside the bloc. Pharmaceuticals account for 15% of the EU's goods exports to the US. They are followed by the auto sector. Until there is more clarification on potential US tariffs on the pharma sector's products, 'the auto sector seems to be the most vulnerable to US tariffs as there doesn't seem to be any major exemptions planned,' said Savary. The industry has been slapped with a 25% tariff in April. 'Tariffs alone could shave around 8% off total EU trade volumes over the next five years,' said Rory Fennessy, Senior Economist at Oxford Economics, in a recent report. Countries with the highest value in goods exports to the US, facing the biggest threat to their economies, include Germany, Ireland, Italy, France and the Netherlands. The German economy relies heavily on exports, boosted by the country's motor vehicle sector. Nearly one-quarter (22.7%) of the total German exports are heading to the US. 'Germany stands out as the major European economy likely to be hit hardest by US tariffs, and we expect GDP growth to slump in the second and third quarters," Andrew Hunter, Associate Director and Senior Economist at Moody's Ratings, said to Euronews Business. Hunter also added that smaller economies, including Austria and others in central and eastern Europe, 'which are heavily integrated into Germany's industrial supply chains, will also be hit hard'. According to Bruegel, after 2025, the long-term negative impact of the tariffs could be around 0.4% of the GDP in Germany, once 'the effect has fully built up and initial short-term effects dissipated,' said Niclas Frederic Poitiers, Research Fellow at Bruegel. 'For France, the average effect would be around 0.25% of GDP.' Uncertainty could lead to lost investments and jobs across the entire 27-member bloc. Hunter said that, 'even for those countries where direct exposure to US exports is relatively limited, such as France or Spain, growth is still likely to be weighed down by global weakness and uncertainty. Regarding long-term impacts, Ireland stands out as one of the most affected countries, as more than half of its goods exports (53.7%) are directed towards the US market. A lot depends on whether the pharmaceutical sector will be hit with tariffs. If so, 'Ireland will be the EU economy most at risk from these tariffs,' said Mathieu Savary, chief strategist for our European Investment Strategy at BCA Research. How pharma tariffs could hit the European economy in particular The research-based pharmaceutical industry is a key asset of the European economy. It is one of Europe's top-performing high-technology sectors. It contributed €311 billion in gross value added (GVA) and 2.3 million jobs directly and indirectly to the European Union's economy in 2022, according to a recent study by PWC. And the US market is crucial to the European pharma sector. According to the European Federation of Pharmaceutical Industries and Associations, in 2021, North America accounted for 49.1% of world pharmaceutical sales compared with 23.4% for Europe. And more than one-third of EU pharma exports are going to the US. If the pharma sector is hit by a 25% tariff, as it is expected by Moody's in the coming months, 'most exposed would be a number of smaller European economies like Denmark, Belgium, Slovenia and Ireland, which are generally where we think the risks of recession in Europe are highest,' Hunter said. BCA Research's chief strategist added that in this case, 'Ireland is particularly exposed to this risk,' citing that exports to the US represent 18% of Ireland's GDP, and pharma exports represent nearly 55% of Irish exports. According to BCA, the impact 'could curtail 4% to 5% to growth over time'. Bruegel estimated that Ireland's cumulative real GDP loss could be 3% by 2028. The think tank also singled out the country as the most vulnerable regarding the impact of the US tariffs on employment. Regarding how vulnerable a country is to job losses in light of US tariffs, Bruegel said that Italy was the second most-exposed country, with a high exposure in transport equipment and a high level of exposed employment in fashion and car manufacturing. Italy would also have high exposure in pharmaceuticals. Would there be a 200% tariff on pharma products? Trump said on Tuesday that pharmaceutical products imported to the US are facing a 200% tariff, without disclosing any further details. According to BCA's Savary, it is not likely, because 'that would massively increase the cost of healthcare for US consumers, which is already a major issue for voters.' He sees it as a 'strong message to foreign pharma companies to adjust their pricing down and invest into producing their drugs in the US.' Savary expects 'that FDIs into the US and drug prices reduction announcements will be the end result of these talks and threats'. 'The pressure is now on for drug companies to expand US production facilities so they are effectively on the doorstep of American customers,' said Dan Coatsworth, investment analyst at AJ Bell.
Fibre2Fashion
18-06-2025
- Science
- Fibre2Fashion
Switzerland's Syngenta unveils breakthrough herbicide for grass weeds
Weeds compete with crops for resources such as water, nutrients and sunlight, and lower yields in major crops by as much as 43% (Savary, 2019). The evolution of herbicide resistance in many weed species today poses a serious and growing threat to many farmers around the world, limiting yield and – in extreme cases – destroying the value of the land. Innovation in herbicide technologies has resurged in importance and urgency, reflecting the value of such technologies in controlling weeds and improving the sustainability of farming operations. Syngenta has unveiled metproxybicyclone, a novel herbicide classified as a new ACCase-inhibitor subclassâ€'the first in nearly 20 years. Designed to combat resistant grass weeds, it's expected to launch in Argentina in 2026. Developed in the UK, the herbicide reflects Syngenta's 'Safer by Design' approach, aiming to boost yields and sustainability in crop protection. Syngenta, a global leader in agricultural innovation, announced that its latest weed control solution, metproxybicyclone, has been recognized under a new chemical subclass of herbicides. The decision, by the Herbicide Resistance Action Committee (HRAC) and the Weed Science Society of America (WSSA), reflects metproxybicyclone's distinction as the fourth generation of ACCase-inhibitors, an important class of herbicides. The third generation of ACCase-inhibitors, represented by Syngenta's leading molecule pinoxaden, was launched in 2006; the nearly two-decade long gap in ACCase subclass innovation reflects in part the extreme challenges in finding new, effective and safe solutions. 'Herbicide resistance has been officially reported in 75 countries and affects farmers of more than 100 crops; of the 273 weed species afflicted, 40 percent are grass weeds,' said Camilla Corsi, Syngenta's Global Head of Research and Development. 'At Syngenta, we push the boundaries of crop protection science to deliver solutions farmers need. Years ago, our scientists foresaw that certain grass weeds in Argentina and Brazil would likely evolve resistance to existing herbicides, and since then we've raced to bring a solution to market – in time to support soybean and cotton farmers who now confront this challenge.' Subject to regulatory approvals, the new herbicide is currently expected to be introduced in Argentina in 2026. The novel herbicide was invented at Syngenta's International Research Centre at Jealott's Hill, UK. By leveraging Syngenta's extensive expertise in ACCase-inhibitors and state-of-the-art computer modelling, scientists precisely designed a new subclass of herbicide capable of controlling grass weeds that had evolved resistance to herbicides such as glyphosate and clethodim, while optimizing the molecule's sustainability profile. The approach reflects Syngenta's 'Safer by Design' research philosophy that guides Syngenta's efforts in delivering higher yields while lowering the impact to the planet through more sustainable technologies. Syngenta is widely regarded for its leading pipeline of innovative agricultural solutions. Its portfolio of crop protection solutions includes products based on ADEPIDYN technology, PLINAZOLIN technology and TYMIRIUM technology, as well as a wide and expanding array of biological and digital solutions. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (HU)
USA Today
20-05-2025
- Sport
- USA Today
Iowa baseball earns eight All-Big Ten honors
Iowa baseball earns eight All-Big Ten honors With the Big Ten Baseball Tournament underway from Charles Schwab Field in Omaha, Neb., the conference announced its numerous regular-season honors Tuesday morning, for which eight Iowa baseball (32-20-1, 21-9 Big Ten) players earned recognition. Although the Hawkeyes faltered mightily down the stretch, which ultimately cost the program a chance at the conference regular-season crown and top overall seed in the postseason tournament, there is still lots to celebrate regarding Iowa's performance throughout their 21-9 record within the Big Ten. Beginning with the strength of the Hawkeyes team, junior starting pitchers Cade Obermueller and Aaron Savary were both named to the All-Big Ten First Team. At the same time, redshirt senior Reece Beuter was placed on the All-Big Ten Second Team. Obermueller earned first-team All-Big Ten honors after going 4-3 with a 3.30 ERA in 14 regular-season starts, where he posted four quality starts and struck out 107 batters over 76.1 innings. His 107 punchouts lead the Big Ten and rank fourth in program history in a single season. Savary earned his recognition after going 7-1, including 5-0 in conference play, with a 3.74 ERA in 14 regular-season starts. The right-hander recorded a team-high six quality starts and struck out 81 batters in 77 innings. Beuter earned second-team honors following a 6-0 record and ranking fourth in the conference with a 3.14 ERA in 13 regular-season starts. He held opponents to a .196 batting average and fanned 66 over 63 innings on the hill. The conference's recognition of the Hawkeyes' pitching makes Iowa the only school to have all three weekend starters named to the All-Big Ten lists. Joining Savary and Obermueller in the First Team class is redshirt sophomore Reese Moore, who finished with a batting average of .319, .454 on-base percentage, and .577 slugging percentage at the plate to go along with a team-leading nine home runs, two triples, and 45 RBIs. During conference play, Moore hit a batting average of .305 with nine doubles, six home runs, and 26 RBIs. Accompanying Beuter on the Second Team list is graduate student Daniel Rogers, who finished with a batting average of .262, .405 on-base percentage, and .470 slugging percentage with 11 doubles, seven home runs, and 41 RBIs in 47 regular-season starts in his lone season in Iowa City. Senior Ben Wilmes was the lone Hawkeye to earn Third Team honors as the Johnston, Iowa, native slashed a batting average of .313, .402 on-base percentage, and .513 slugging percentage to accompany seven home runs, 16 doubles, one triple, and a career-high 41 RBIs. Redshirt freshman Jaixon Frost was named to the All-Freshman Team after he finished with a batting average of .316, .407 on-base percentage, and .500 slugging percentage with 23 RBIs, 12 extra base hits, and three home runs in 37 regular-season appearances. The Kellerton, Iowa, native also hit .309 in Big Ten play with 15 RBIs, six doubles, and two home runs. Rounding out the eight Hawkeyes honored is redshirt freshman Max Burt, who was selected as Iowa's Big Ten Sportsmanship recipient. The distinction is presented to student-athletes who display sportsmanship and ethical behavior, are in good academic standing, and demonstrate good citizenship outside of athletics. Iowa's seven All-Big Ten selections give head coach Rick Heller 47 selections in his 12 seasons in Iowa City. Heller has coached at least one first-team All-Big Ten selection in 10 of his 11 seasons when awards were handed out (there were no honors in 2020 due to the implications of the COVID-19 pandemic). The third-seeded Hawkeyes' first game of the 2025 Big Ten Baseball Tournament will be tomorrow vs. No. 10 seed Rutgers (28-27, 15-15) at 6 p.m. CT from Charles Schwab Field. The entire tournament will be broadcast on the Big Ten Network. All of Iowa's games can also be heard through the Hawkeyes Radio Network alongside play-by-play voice John Leo and color analyst John Evans. Contact/Follow us @HawkeyesWire on X and like our page on Facebook to follow ongoing coverage of Iowa news, notes, and opinions. Follow Scout on X: @SpringgateNews
